Synonyms:cilostazol, 73963-72-1, Pletal, Cilostazole, Pletaal, OPC-13013, Cilostazolum, OPC-21, Cilostazolum [INN-Latin], OPC 13013, OPC 21, 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one, CHEBI:31401, 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone, NSC-758936, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril, MLS000028470, DTXSID9045132, 1073608-02-2, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one, 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one, N7Z035406B, NCGC00015207-07, SMR000058428, DTXCID7025132, 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, 2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-, CAS-73963-72-1, Pletal (TN), SR-01000003107, BRN 3632107, UNII-N7Z035406B, 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-, Cilostazol,(S), Cilostazol-[d11], MFCD00866780, Cilostazol [USAN:USP:INN:BAN:JAN], Tocris-1692, CILOSTAZOL [MI], Opera_ID_488, CILOSTAZOL [INN], CILOSTAZOL [JAN], Spectrum2_001118, Spectrum3_001170, Spectrum4_000772, Spectrum5_001762, CILOSTAZOL [USAN], Lopac-C-0737, CILOSTAZOL [VANDF], CHEMBL799, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, C 0737, CILOSTAZOL [MART.], CILOSTAZOL [USP-RS], CILOSTAZOL [WHO-DD], Lopac0_000218, REGID_for_CID_2754, SCHEMBL16128, BSPBio_002759, KBioGR_001184, MLS000758281, MLS000759507, MLS001076067, MLS002153891, SPECTRUM1505230, SPBio_001256, Cilostazol (JP17/USP/INN), GTPL7148, CILOSTAZOL [ORANGE BOOK], HSDB 8312, KBio3_002259, BCPP000279, CILOSTAZOL [USP MONOGRAPH], HMS1922N15, HMS2093M14, HMS2096F16, HMS2234C06, HMS3260L17, HMS3268O09, HMS3412B18, HMS3654J13, HMS3676B18, HMS3713F16, Pharmakon1600-01505230, ACT02663, BCP03724, Tox21_110098, Tox21_500218, BDBM50225508, CCG-39646, NSC758936, s1294, AKOS015855512, Cilostazol, >=98% (HPLC), powder, OPC 13013; OPC 21; Pletaal, Tox21_110098_1, AC-4334, AM90304, BCP9000530, CS-1759, DB01166, KS-5154, LP00218, NSC 758936, SDCCGSBI-0050206.P003, 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-, 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-, NCGC00015207-01, NCGC00015207-02, NCGC00015207-03, NCGC00015207-04, NCGC00015207-05, NCGC00015207-06, NCGC00015207-08, NCGC00015207-09, NCGC00015207-10, NCGC00015207-11, NCGC00015207-12, NCGC00015207-25, NCGC00022153-02, NCGC00022153-04, NCGC00022153-05, NCGC00022153-06, NCGC00022153-07, NCGC00260903-01, HY-17464, BCP0726000145, RETAL;PLETAL;OPC 21;PLETAAL;Cilostal, SBI-0050206.P002, C2587, EU-0100218, FT-0602474, FT-0645036, FT-0665038, SW199053-2, D01896, F20538, AB00382988-14, AB00382988_15, AB00382988_16, A837982, Q258591, Q-200854, SR-01000003107-2, SR-01000003107-4, SR-01000003107-7, BRD-K67017579-001-04-2, BRD-K67017579-001-05-9, BRD-K67017579-001-07-5, BRD-K67017579-001-13-3, BRD-K67017579-001-17-4, SR-01000003107-10, Cilastatin sodium, Antibiotic for Culture Media Use Only, Z1501485368, Cilostazol, United States Pharmacopeia (USP) Reference Standard, 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril, Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material, 6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)QUINOLINE-2,3(1H,4H)-DIONE, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
Pubchem:PUBCHEM:2754
Id:8c1808ae-2991-5e5a-8215-39dae25bf993
Description:nan
